JPH05178753A - External preparation for skin pruritus - Google Patents
External preparation for skin pruritusInfo
- Publication number
- JPH05178753A JPH05178753A JP3323677A JP32367791A JPH05178753A JP H05178753 A JPH05178753 A JP H05178753A JP 3323677 A JP3323677 A JP 3323677A JP 32367791 A JP32367791 A JP 32367791A JP H05178753 A JPH05178753 A JP H05178753A
- Authority
- JP
- Japan
- Prior art keywords
- pruritus
- test
- cream
- external preparation
- day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
【０００１】[0001]
【産業上の利用分野】本発明は、老人性皮膚▲そう▼痒
症、冬季▲そう▼痒症、アレルギー疾患及び糖尿病を要
因とする皮膚▲そう▼痒症用の外用剤に関するものであ
る。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to an external preparation for pruritus of the skin caused by senile pruritus itch, winter pruritus, pruritus, allergic diseases and diabetes.
【０００２】[0002]
【従来技術】「皮膚▲そう▼痒症」とは、皮疹のみられ
ない▲そう▼痒（かゆみ）のみを主症状とする疾患のこ
とをいう。皮膚▲そう▼痒症は、全身性（汎発性）と局
所性（限局性）に大別することができ、前者では肝疾
患、腎疾患、内分泌疾患、精神・神経系疾患、妊娠、ア
レルギー性疾患、老人性皮膚▲そう▼痒症、冬季▲そう
▼痒症等が知られ、背景には各種の内臓疾患が存在する
ことが多い。後者としては肛囲▲そう▼痒症、陰門皮膚
▲そう▼痒症等が知られている。これらの治療方法とし
ては、抗ヒスタミン剤、抗アレルギー剤等の単独又は併
用による内服や、保湿性を有する尿素軟膏、抗ヒスタミ
ン剤含有軟膏等の塗布が行われている。2. Description of the Related Art "Skin itch pruritus" refers to a disease whose only main symptom is pruritus (itch), which is not a rash. Pruritus dermatitis can be broadly classified into systemic (general) and local (localized). In the former case, liver disease, renal disease, endocrine disease, mental / nervous disease, pregnancy, allergy. Genital diseases, pruritus senile skin, pruritus in winter, etc. are known, and various visceral diseases are often present in the background. As the latter, it is known that the anal circumference pruritus, vulvar skin pruritus and the like. As a therapeutic method for these, oral administration of antihistamines, antiallergic agents, etc., alone or in combination, and application of moisturizing urea ointment, antihistamine-containing ointment, etc. are performed.
【０００３】[0003]
【発明が解決しようとする課題】しかしながら外用剤の
場合は、基剤による保湿効果により多少とも止痒効果が
期待できるが、外用剤による薬効はほとんど期待できな
いでいる。また抗ヒスタミン剤含有軟膏は場合によって
は、接触皮膚炎を生じるというような不都合がある。そ
こで本発明はかかる従来技術の欠点に鑑みなされたもの
で、外用剤として皮膚▲そう▼痒症に有効であり、かつ
副作用のない外用剤を提供することを目的とする。However, in the case of the external preparation, the anti-pruritic effect can be expected to some extent due to the moisturizing effect of the base, but the pharmaceutical effect of the external preparation can hardly be expected. In addition, the antihistamine-containing ointment has the disadvantage that contact dermatitis may occur in some cases. Therefore, the present invention has been made in view of the above-mentioned drawbacks of the prior art, and an object thereof is to provide an external preparation that is effective for pruritus dermatitis and has no side effects as an external preparation.
【０００４】[0004]
【課題を解決するための手段】すなわち本発明は、薬効
成分としてヒノキチオール又はその誘導体を選択し、こ
れに外用剤としての基剤を混合してなる皮膚▲そう▼痒
症用外用剤により本目的を達成する。薬効成分であるヒ
ノキチオール又はその誘導体としては、0.01〜1.00重量
％配合する。これは1.00重量％以上の場合でもその効果
に大差が見られないこと、0.01重量％未満の場合には、
効果が得られないためである。外用剤の剤形としては、
従来の皮膚外用剤に用いられるものであれば良く、例え
ば液剤（ローション等）、乳剤性基剤（クリーム、軟
膏）、パウダー、スプレー、ゲル剤、貼付剤等があげら
れる。基剤としては、グリセリン脂肪酸エステル、ショ
糖脂肪酸エステル、リン脂質、炭化水素、脂肪酸、高級
アルコール、エステル、シリコン油、油脂、多価アルコ
ール、カルボキシビニルポリマー、カルボキシメチルセ
ルロース等のゲル化剤、酸化亜鉛、ナイロンパウダー、
ポリエチレンパウダー等のパウダーを代表的なものとし
て挙げることができる。Means for Solving the Problem That is, the present invention provides an external preparation for skin itch pruritus, which comprises hinokitiol or its derivative selected as a medicinal component and mixing it with a base as an external preparation. To achieve. As a medicinal ingredient, hinokitiol or its derivative is added in an amount of 0.01 to 1.00% by weight. This means that even if it is 1.00% by weight or more, there is no great difference in its effect, and if it is less than 0.01% by weight,
This is because the effect cannot be obtained. As the dosage form of the external preparation,
It may be used as a conventional external preparation for skin, and examples thereof include solutions (lotions and the like), emulsion bases (creams and ointments), powders, sprays, gels, patches and the like. As the base, glycerin fatty acid ester, sucrose fatty acid ester, phospholipid, hydrocarbon, fatty acid, higher alcohol, ester, silicone oil, oil and fat, polyhydric alcohol, carboxyvinyl polymer, gelling agent such as carboxymethyl cellulose, zinc oxide , Nylon powder,
A powder such as polyethylene powder can be mentioned as a typical one.
【０００５】[0005]
【作用】本発明にかかるヒノキチオール又はその誘導体
を含有させた外用剤を▲そう▼痒症状を示す部分に塗布
等で付着させる。すると、外用剤を付着させた部分にお
けるかゆみがおさまると共に、ヒノキチオールのもつ殺
菌作用により、皮膚に付着している細菌等を殺菌する。The external preparation containing the hinokitiol or its derivative according to the present invention is adhered to a portion showing pruritus by applying or the like. Then, itching in the portion to which the external preparation is attached is subsided, and the bactericidal action of hinokitiol sterilizes bacteria and the like attached to the skin.
【０００６】[0006]
〔実施例１〕下記に示す組成からなるヒノキチオールを
配合したクリーム（本発明１）を作成し、これと10％尿
素クリームの市販品（比較例１）とを製剤の識別が不可
能な同一外観のラミネートチューブにそれぞれ30ｇを充
填し、それぞれのクリームに対応してＡ及びＢのラベル
を貼り、さらにＡ、Ｂそれぞれにつき、右及び左と表示
したラベルを各15づつ貼った。これらのクリームを老人
性▲そう▼痒症（60歳以上)の３０人を対象として左右
対象に同程度の▲そう▼痒がみられる部位を選び、右用
の製剤を右側、左用の製剤を左側の被験部位に１日２〜
３回単純塗布しながら二週間使用した後の感応テストを
行ったところ表１に示す通りとなった。観察は試験初日
と試験開始２週間後に行った。また試験初日の状態と比
較してどの程度症状が改善されたかについて、治癒、改
善、やや改善、変わらず、悪化の５段階評価で判定し
た。 クリームＡの処方（100g） 成 分 配合量 ヒノキチオール 0.1 グリチルレチン酸 0.1 モノステアリン酸グリセリン 6.0 モノステアリン酸エチレングリコール 6.0 スクワラン 4.0 パルミチン酸イソプロピル 4.0 エデト酸２ナトリウム 0.05 パラオキシ安息香酸ブチル 0.1 精製水 残量[Example 1] A cream (Invention 1) containing hinokitiol having the composition shown below was prepared, and the same appearance as the commercial product of 10% urea cream (Comparative Example 1) was impossible to identify. Each of the laminated tubes was filled with 30 g and labeled A and B corresponding to each cream, and 15 labels labeled right and left for A and B respectively. These creams are intended for 30 people with senile pruritus (60 years old or older), and select the sites where similar pruritus is seen on the left and right, and the right formulation and the left formulation are selected. 2 to 1 day on the test site on the left side
A sensitivity test was carried out after two weeks of simple application with simple application three times. The results are shown in Table 1. The observation was performed on the first day of the test and two weeks after the start of the test. In addition, how much the symptoms were improved as compared to the condition on the first day of the test was judged by a 5-grade evaluation of healing, improvement, slight improvement, no change, and deterioration. Formulation of Cream A (100g) Composition Blend amount Hinokitiol 0.1 Glycyrrhetinic acid 0.1 Glycerin monostearate 6.0 Ethylene glycol monostearate 6.0 Squalane 4.0 Isopropyl palmitate 4.0 Disodium edetate 0.05 Butyl paraoxybenzoate 0.1 Purified water Remaining amount
【０００６】[0006]
【表１】 [Table 1]
【０００７】▲そう▼痒の程度は、自覚症状により高
度：３（＋＋＋）、中程度：２（＋＋）、軽度１：
（＋）、軽微：0.5（±）、なし：０（−）の５段階で
評価した。その結果クリーム使用による改善率は、評価
改善以上でみた場合に、クリームＡ（本発明１）が６０
％、クリームＢ（比較例１）が４０％であった。▲ Yes ▼ The degree of itching depends on the subjective symptoms: high: 3 (+++), moderate: 2 (++), mild 1:
(+), Minor: 0.5 (±), None: 0 (-). As a result, the improvement rate by using the cream is 60 when the cream A (invention 1) is more than the evaluation improvement.
%, And cream B (Comparative Example 1) was 40%.
【０００８】〔実施例２〕下記に示す組成からなるクリ
ームＡ（本発明２）及びクリームＢ（本発明３）並びに
基剤だけのクリームＣ（比較例２）を作成し、これらを
製剤の識別が不可能な同一外観のラミネートチューブに
それぞれ30ｇを充填し、それぞれのクリームに対応して
Ａ、Ｂ、Ｃのラベルを貼り、さらにＡ、Ｂ、Ｃそれぞれ
につき、右及び左と表示したラベルを各10づつＣについ
ては各20づつ貼った。これらのＡ，Ｃ及びＢ、Ｃの組合
せのクリームを老人性▲そう▼痒症（60歳以上)の20人
を対象として左右対象に同程度の▲そう▼痒がみられる
部位を選び、右用の製剤を右側、左用の製剤を左側の被
験部位に１日２〜３回単純塗布しながら二週間使用した
後の感応テストを行ったところ表２に示す通りとなっ
た。観察は試験初日と試験開始２週間後に行った。また
試験初日の状態と比較してどの程度症状が改善されたか
について、治癒、改善、やや改善、変わらず、悪化の５
段階評価で判定した。 クリームＡ、Ｂ、Ｃの処方（100g） 成 分 クリームＡ クリームＢ クリームＣ 本発明２ 本発明３ 比較例２ ヒノキチオール 0.5 1.0 − ステアリン酸グリチルレチニル 0.5 0.5 0.5 モノステアリン酸グリセリン 6.0 6.0 6.0 モノステアリン酸エチレングリコール 6.0 6.0 6.0 スクワラン 4.0 4.0 4.0 パルミチン酸イソプロピル 4.0 4.0 4.0 エデト酸２ナトリウム 0.05 0.05 0.05 パラオキシ安息香酸ブチル 0.1 0.1 0.1 精製水 残量 残量 残量Example 2 Cream A (Invention 2) and Cream B (Invention 3) having the composition shown below and Cream C (Comparative Example 2) containing only the base were prepared, and these were used to identify the formulations. It is impossible to fill a laminated tube of the same appearance with 30 g each, label A, B, C corresponding to each cream, and label A, B, C as right and left respectively. About 10 each C, 20 each was stuck. The cream of the combination of A, C, B, and C is selected for 20 people with senile ▲ pruritus (60 years old or older), and the right ▲ ▼ pruritus is selected on the right and left. Table 2 shows the results of a sensitization test after two weeks of simple application of the preparations for the right side and the preparations for the left side to the test site on the left side two to three times a day for two weeks. The observation was performed on the first day of the test and two weeks after the start of the test. In addition, as to how much the symptoms were improved compared to the condition on the first day of the test, it was cured, improved, slightly improved, remained unchanged, and deteriorated.
It was judged by graded evaluation. Formulation of Creams A, B and C (100 g) Component Cream A Cream B Cream C Present Invention 2 Present Invention 3 Comparative Example 2 Hinokitiol 0.5 1.0-Glycyrrhetinyl stearate 0.5 0.5 0.5 Glycerin monostearate 6.0 6.0 6.0 Ethylene glycol monostearate 6.0 6.0 6.0 Squalane 4.0 4.0 4.0 Isopropyl palmitate 4.0 4.0 4.0 Disodium edetate 0.05 0.05 0.05 Butyl paraoxybenzoate 0.1 0.1 0.1 Purified water Remaining amount Remaining amount Remaining amount
【０００９】[0009]
【表２】 [Table 2]
【００１０】その結果クリームＡ、Ｂ、Ｃ使用による改
善率は、評価が改善以上でみた場合に、クリームＡ（本
発明２）が75％、クリームＢ（本発明３）が70％、クリ
ームＣ（比較例２）が５％又は０％であった。また、ヒ
ノキチオールの成分が0.5重量％の場合と1.0重量％の場
合とでは差異がみられなかった。As a result, the improvement rate by using creams A, B and C is 75% for cream A (invention 2), 70% for cream B (invention 3) and 70% for cream C when the evaluation is improved or better. (Comparative Example 2) was 5% or 0%. Moreover, no difference was observed between the case where the hinokitiol component was 0.5% by weight and the case where it was 1.0% by weight.
【００１１】〔実施例３〕以下の組成からなるクリーム
（本発明４）を作成し、これと市販の10％尿素クリーム
（比較例１）を製剤の識別が不可能な同一外観のラミネ
ートチューブにそれぞれ30ｇを充填し、それぞれのクリ
ームに対応してＡ及びＢのラベルを貼り、さらにＡ、Ｂ
それぞれにつき、右及び左と表示したラベルを各15づつ
貼った。これらのクリームを冬季▲そう▼痒症の３０人
を対象として左右対象に同程度の▲そう▼痒がみられる
部位を選び、右用の製剤を右側、左用の製剤を左側の被
験部位に１日２〜３回単純塗布しながら二週間使用した
後の感応テストを行ったところ表３に示す通りとなっ
た。観察は試験初日と試験開始２週間後に行った。また
試験初日の状態と比較してどの程度症状が改善されたか
について、自覚症状により、高度：３（＋＋＋）、中程
度：２（＋＋）、軽度：１（＋）、軽微：0.5（±）、
なし：０（−）の５段階評価で判定した。 クリームＡの処方（本発明４） 成 分 配合量 ヒノキチオールのカリウム塩 0.2 ステアリン酸グリチルレチニル 0.1 モノステアリン酸グリセリン 6.0 モノステアリン酸エチレングリコール 6.0 スクワラン 4.0 パルミチン酸イソプロピル 4.0 エデト酸２ナトリウム 0.05 パラオキシ安息香酸ブチル 0.1 精製水 残量Example 3 A cream (Invention 4) having the following composition was prepared, and this and a commercially available 10% urea cream (Comparative Example 1) were put into a laminated tube having the same appearance in which the formulations cannot be identified. Fill 30g each, label A and B corresponding to each cream, then A, B
Fifteen labels each labeled right and left were attached to each. These creams were selected in winter for 30 people with pruritus and left and right subjects were selected to have similar pruritus, and the right formulation was applied to the right side and the left formulation was applied to the left test site. A sensitization test was conducted after two weeks of simple application two to three times a day and the results are shown in Table 3. The observation was performed on the first day of the test and two weeks after the start of the test. Also, depending on the subjective symptoms, how much the symptoms were improved compared to the state on the first day of the test, altitude: 3 (++), moderate: 2 (++), mild: 1 (+), minor: 0.5 (±) ,
None: It was judged by a 5-level evaluation of 0 (-). Formulation of Cream A (Invention 4) Component Ingredient Content Potassium salt of hinokitiol 0.2 Glycyrrhetinyl stearate 0.1 Glycerin monostearate 6.0 Ethylene glycol monostearate 6.0 Squalane 4.0 Isopropyl palmitate 4.0 Disodium edetate 0.05 Butyl paraoxybenzoate 0.1 Purified Water level
【００１２】[0012]
【表３】 この結果、▲そう▼痒の程度は30人平均で使用前１．４
８であったものがクリームＡ使用後は０．４５と改善さ
れ、クリームＢ（比較例１）では０．８７というように
改善された。[Table 3] As a result, ▲ So ▼ The degree of pruritus was 30 people average 1.4 before use.
The value of 8 was improved to 0.45 after the use of Cream A, and was improved to 0.87 for Cream B (Comparative Example 1).
【００１３】〔実施例４〕以下の組成からなるローショ
ンＡ（本発明５）と、比較用としてヒノキチオールを含
まない基剤だけのローションＢ（比較例３）を作成し、
これらを製剤の識別が不可能な褐色のガラス瓶にそれぞ
れ50ｇづつ充填し、それぞれのローションに対応して
Ａ、Ｂのラベルを貼り、さらにＡ、Ｂそれぞれにつき右
及び左と表示したラベルを各15づつ貼った。これらロー
ションＡ、Ｂについて、冬季▲そう▼痒症の３０人を対
象として左右対象に同程度の▲そう▼痒がみられる部位
を選び、右用の製剤を右側、左用の製剤を左側の被験部
位に１日２〜３回単純塗布しながら二週間使用した後の
感応テストを行ったところ表４に示す通りとなった。観
察は試験初日と試験開始２週間後に行った。また試験初
日の状態と比較してどの程度症状が改善されたかについ
て、治癒、改善、やや改善、変わらず、悪化の５段階評
価で判定した。 ローションＡ（本発明５）、Ｂ（比較例３）の処方 配 合 量 成 分 ローションＡ ローションＢ ヒノキチオール 0.03 リン酸２水素カリウム 0.6 0.6 リン酸１水素ナトリウム 0.2 0.2 グリセリン 3.0 3.0 パラオキシ安息香酸メチル 0.1 0.1 精製水 残量 残量Example 4 A lotion A (invention 5) having the following composition and a lotion B (comparative example 3) containing only a base containing no hinokitiol were prepared for comparison.
Each of these is filled with 50 g of each in a brown glass bottle whose formulation cannot be identified, labeled A and B corresponding to each lotion, and labeled with right and left for A and B, respectively. I pasted them one by one. With regard to these lotions A and B, 30 people with pruritus in the winter ▲ were selected for the left and right subjects with similar pruritus, and the right preparation was used on the right and the left preparation was tested on the left. A sensitivity test was conducted after two weeks of simple application to the site 2-3 times a day. The results are shown in Table 4. The observation was performed on the first day of the test and two weeks after the start of the test. In addition, how much the symptoms were improved as compared to the condition on the first day of the test was judged by a 5-grade evaluation of healing, improvement, slight improvement, no change, and deterioration. Formulations of lotions A (invention 5) and B (comparative example 3) Component Content Lotion A lotion B Hinokitiol 0.03 Potassium dihydrogen phosphate 0.6 0.6 Sodium monohydrogen phosphate 0.2 0.2 Glycerin 3.0 3.0 Methyl paraoxybenzoate 0.1 0.1 Purified water Remaining amount Remaining amount
【００１４】[0014]
【表４】 [Table 4]
【００１５】本発明にかかるローション使用による改善
率は改善以上でみた場合６０％であるのに対し、比較例
にかかるものは３％であった。The improvement rate by using the lotion according to the present invention was 60% in the case of improvement or more, whereas it was 3% in the comparative example.
【００１６】〔実施例５〕以下の組成からなるローショ
ン（本発明６）を作成し、褐色のガラス瓶にそれぞれ50
ｇづつ充填し右及び左と表示したラベルを各10づつ貼っ
た。このローションについて、糖尿病患者で▲そう▼痒
症の２０人を対象として左右対象に同程度の▲そう▼痒
がみられる部位を選び、右用の製剤を右側、左用の製剤
を左側の被験部位に１日２〜３回単純塗布しながら二週
間使用した後の感応テストを行ったところ表５に示す通
りとなった。観察は試験初日と試験開始２週間後に行っ
た。また試験初日の状態と比較してどの程度症状が改善
されたかについて、治癒、改善、やや改善、変わらず、
悪化の５段階評価で判定した。 ローション（100g）の処方 成 分 配合量 ヒノキチオールのナトリウム塩 0.05 グリチルリチン酸ジカリウム 0.05 １，３ブチレングリコール 5.0 パラオキシ安息香酸メチル 0.1 精製水 残量[Example 5] A lotion (invention 6) having the following composition was prepared, and 50 ml each was put in a brown glass bottle.
Labels labeled "right" and "left" were applied 10 times each. About this lotion, 20 diabetic patients with pruritus were selected as the sites with similar pruritus on left and right subjects, and the right formulation was used on the right and the left formulation was tested on the left. A sensitization test was conducted after 2 weeks of use while simply applying 2 to 3 times a day to Table 5. The observation was performed on the first day of the test and two weeks after the start of the test. Also, regarding how much the symptoms improved compared to the condition on the first day of the test, healing, improvement, slight improvement, unchanged,
It was judged by a 5-grade evaluation of deterioration. Formulation of lotion (100g) Ingredients Ingredients Sodium salt of hinokitiol 0.05 Dipotassium glycyrrhizinate 0.05 1,3 Butylene glycol 5.0 Methyl paraoxybenzoate 0.1 Purified water Remaining amount
【００１７】[0017]
【表５】 [Table 5]
【００１８】本発明にかかるローション使用による改善
率は、改善以上でみた場合７５％であった。The improvement rate by using the lotion according to the present invention was 75% in the case of improvement or more.
【００１９】〔実施例６〕以下の組成からなるパウダー
（本発明７）を作成し、これを褐色のガラス瓶にそれぞ
れ50ｇづつ充填し右及び左と表示したラベルを各10づつ
貼った。このパウダーについて、糖尿病患者で▲そう▼
痒症の２０人を対象として左右対象に同程度の▲そう▼
痒がみられる部位を選び、右用の製剤を右側、左用の製
剤を左側の被験部位に１日２〜３回単純塗布しながら二
週間使用した後の感応テストを行ったところ表６に示す
通りとなった。観察は試験初日と試験開始２週間後に行
った。また試験初日の状態と比較してどの程度症状が改
善されたかについて、治癒、改善、やや改善、変わら
ず、悪化の５段階評価で判定した。 パウダーの処方（100g） 成 分 配合量 ヒノキチオール 0.1 エチルアルコール 2.0 二酸化チタン 5.0 ナイロン12 残量Example 6 A powder (Invention 7) having the following composition was prepared, and 50 g of each powder was filled in a brown glass bottle, and 10 labels each were labeled as right and left. About this powder in diabetics
Targeting 20 people with pruritus, the left and right subjects have the same degree.
Table 6 shows the results of a sensitization test after selecting the site where pruritus was observed, applying the formulation for the right on the right side and the formulation for the left on the test site on the left 2-3 times a day for two weeks while simply applying the formulation. It became a street. The observation was performed on the first day of the test and two weeks after the start of the test. In addition, how much the symptoms were improved as compared to the condition on the first day of the test was judged by a 5-grade evaluation of healing, improvement, slight improvement, no change, and deterioration. Prescription of powder (100g) Composition Blend amount Hinokitiol 0.1 Ethyl alcohol 2.0 Titanium dioxide 5.0 Nylon 12 Remaining amount
【００２０】[0020]
【表６】 [Table 6]
【００２１】その結果パウダー使用による▲そう▼痒の
改善率は改善以上でみた場合、５５％であった。As a result, the rate of improvement in pruritus caused by the use of powder was 55% when it was more than improved.
【００２２】〔実施例７〕以下の組成からなるゲル剤を
作成し、これをラミネートチューブに50ｇづつ充填し、
このゲル剤を糖尿病患者で▲そう▼痒症の２０人を対象
として左右対象に同程度の▲そう▼痒がみられる部位を
選び、右用の製剤を右側、左用の製剤を左側の被験部位
に１日２〜３回単純塗布しながら二週間使用した後の感
応テストを行ったところ表７に示す通りとなった。観察
は試験初日と試験開始２週間後に行った。また試験初日
の状態と比較してどの程度症状が改善されたかについ
て、治癒、改善、やや改善、変わらず、悪化の５段階評
価で判定した。 ゲル剤の処方（100g） 成 分 配合量 ヒノキチオール 0.1 グリチルリチン酸ジカリウム 0.1 カルボキシビニルポリマー 0.5 水酸化カリウム 0.05 １，３ブチレングリコール 8.0 パラオキシ安息香酸メチル 0.1 精製水 残量Example 7 A gel agent having the following composition was prepared, and a laminated tube was filled with 50 g of each,
This gel is selected from 20 diabetic patients who have pruritus, and choose the site where the same degree of pruritus is seen in the left and right subjects. The right formulation is on the right and the left formulation is on the left. A sensitization test was conducted after 2 weeks of use while simply applying 2 to 3 times a day to Table 7. The observation was performed on the first day of the test and two weeks after the start of the test. In addition, how much the symptoms were improved as compared to the condition on the first day of the test was judged by a 5-grade evaluation of healing, improvement, slight improvement, no change, and deterioration. Gel formulation (100g) Component content Amount of hinokitiol 0.1 Dipotassium glycyrrhizinate 0.1 Carboxyvinyl polymer 0.5 Potassium hydroxide 0.05 1,3 Butylene glycol 8.0 Methyl paraoxybenzoate 0.1 Purified water Remaining amount
【００２３】[0023]
【表７】 [Table 7]
【００２４】その結果ゲル剤使用によるそうようの改善
率は改善以上でみた場合、６５％であった。As a result, the rate of such improvement by using the gel agent was 65% when it was more than improved.
【００２５】〔実施例８〕以下の組成からなる軟膏剤を
作成し、これをラミネートチューブに50ｇづつ充填し、
この軟膏剤をアレルギー性疾患で▲そう▼痒症の２０人
を対象として左右対象に同程度の▲そう▼痒がみられる
部位を選び、右用の製剤を右側、左用の製剤を左側の被
験部位に１日２〜３回単純塗布しながら二週間使用した
後の感応テストを行ったところ表８に示す通りとなっ
た。観察は試験初日と試験開始２週間後に行った。また
試験初日の状態と比較してどの程度症状が改善されたか
について、治癒、改善、やや改善、変わらず、悪化の５
段階評価で判定した。 軟膏剤の処方（100g） 成 分 配合量 ヒノキチオール 0.1 グリチルレチン酸 0.1 ポリオキシエチレン硬化ヒマシ油 1.0 ワセリン 残量[Example 8] An ointment having the following composition was prepared, and 50 g of the ointment was filled in a laminate tube.
This ointment was selected for 20 people with allergic disease ▲ so ▼ Pruritus, and left and right subjects were selected to have similar pruritus, and the right preparation was used on the right side and the left preparation was tested on the left side. A sensitivity test was conducted after two weeks of use while simply applying it to the site 2-3 times a day. The results are shown in Table 8. The observation was performed on the first day of the test and two weeks after the start of the test. In addition, as to how much the symptoms were improved compared to the condition on the first day of the test, it was cured, improved, slightly improved, remained unchanged, and deteriorated.
It was judged by graded evaluation. Prescription of ointment (100g) Component content Amount of hinokitiol 0.1 Glycyrrhetinic acid 0.1 Polyoxyethylene hydrogenated castor oil 1.0 Vaseline balance
【００２６】[0026]
【表８】 [Table 8]
【００２７】その結果軟膏剤使用によるアレルギー性疾
患に関する▲そう▼痒の改善率は改善以上でみた場合、
６０％であった。As a result, regarding the allergic diseases caused by the use of the ointment, the rate of improvement in pruritus is as follows:
It was 60%.
【００２８】[0028]
【効果】以上述べたように本発明にかかる外用剤は、老
人性、冬季性、糖尿病性、アレルギー性の皮膚▲そう▼
痒症に有効であった。[Effect] As described above, the external preparation according to the present invention can be used for senile, winter, diabetic, and allergic skin.
It was effective against pruritus.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.5 識別記号 庁内整理番号 ＦＩ 技術表示箇所 Ａ６１Ｋ 31/12 ＡＤＡ 8413−4Ｃ ─────────────────────────────────────────────────── ─── Continuation of the front page (51) Int.Cl. 5 Identification code Internal reference number FI technical display area A61K 31/12 ADA 8413-4C
Claims (2)
たことを特徴とする皮膚▲そう▼痒症用の外用剤。1. An external preparation for pruritus on the skin, which comprises hinokitiol or a derivative thereof.
1.00w%配合したことを特徴とする皮膚▲そう▼痒症用の
外用剤。2. The hinokitiol or its derivative is added in an amount of 0.01 to
An external preparation for pruritus on the skin characterized by containing 1.00 w%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP32367791A JP3418201B2 (en) | 1991-11-12 | 1991-11-12 | External preparation for skin ▲ so ▼ pruritus |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP32367791A JP3418201B2 (en) | 1991-11-12 | 1991-11-12 | External preparation for skin ▲ so ▼ pruritus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH05178753A true JPH05178753A (en) | 1993-07-20 |
| JP3418201B2 JP3418201B2 (en) | 2003-06-16 |
Family
ID=18157376
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP32367791A Expired - Lifetime JP3418201B2 (en) | 1991-11-12 | 1991-11-12 | External preparation for skin ▲ so ▼ pruritus |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3418201B2 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995034210A1 (en) * | 1994-06-15 | 1995-12-21 | Otsuka Pharmaceutical Co., Ltd. | Hinokitiol-containing composition filled in polyester vessel |
| JP2006219482A (en) * | 2005-01-12 | 2006-08-24 | Rohto Pharmaceut Co Ltd | Itching inhibitor |
| CN103933206A (en) * | 2014-04-20 | 2014-07-23 | 文成县刀锋科技有限公司 | Medicament lotion for treating skin itch of old people |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1656935A1 (en) * | 2004-11-12 | 2006-05-17 | Cognis IP Management GmbH | Use of physiologically active fatty acids for the treatment of pruritus |
-
1991
- 1991-11-12 JP JP32367791A patent/JP3418201B2/en not_active Expired - Lifetime
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995034210A1 (en) * | 1994-06-15 | 1995-12-21 | Otsuka Pharmaceutical Co., Ltd. | Hinokitiol-containing composition filled in polyester vessel |
| JP2006219482A (en) * | 2005-01-12 | 2006-08-24 | Rohto Pharmaceut Co Ltd | Itching inhibitor |
| CN103933206A (en) * | 2014-04-20 | 2014-07-23 | 文成县刀锋科技有限公司 | Medicament lotion for treating skin itch of old people |
Also Published As
| Publication number | Publication date |
|---|---|
| JP3418201B2 (en) | 2003-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1079804B1 (en) | Pharmaceutical compositions comprising an amphoteric surfactant an polypropoxylated cetyl alcohol and a polar drug | |
| JP4610741B2 (en) | An anhydrous topical skin preparation | |
| CA2646667C (en) | Methods of treating hot flashes with formulations for transdermal or transmucosal application | |
| AU669351B2 (en) | Method of the treatment of dry nose syndrome | |
| EP0444492B1 (en) | Topically administered compositions based on high molecular weight hyaluronic acid for treating inflammations of the oral cavity, and for oral cavity hygiene and cosmetic treatment | |
| US20040157936A1 (en) | Anhydrous topical skin preparations | |
| JP2000143486A (en) | Skin preparation for external use | |
| JPH09157172A (en) | Skin external agent and treating agent for eczema | |
| JPH0399019A (en) | Pharmaceutical composition of local use for treatment of capillary fragility | |
| JP3418201B2 (en) | External preparation for skin ▲ so ▼ pruritus | |
| JPH0774152B2 (en) | Liquid for external use on skin | |
| JP2000038352A (en) | Composition for external use | |
| JPH11510824A (en) | Cosmetic method for treatment and prevention of signs of skin aging | |
| JP3689137B2 (en) | Topical agent for treatment of allergic skin disease | |
| US20120238630A1 (en) | Compositions comprising nonsteroidal anti - inflammatory drugs | |
| JP3723728B2 (en) | Skin topical solution | |
| JP2001270828A (en) | External preparation for prevention and therapy of vulgaris acne and cosmetic prepared by formulating the same | |
| JPH0753388A (en) | Bone metabolism improver | |
| JPH10182497A (en) | Composition for external use | |
| Williamson | Comparison of a modified hydrocortisone/urea cream and betamethasone valerate cream in the treatment of dry eczema | |
| JPH09278659A (en) | Preparation for external use for lip | |
| JP2000143518A (en) | Preparation for external use for skin | |
| JP2000143517A (en) | Preparation for external use for skin | |
| JPH10182428A (en) | Composition for external use | |
| JP2000229852A (en) | Skin lotion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080411 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090411 Year of fee payment: 6 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100411 Year of fee payment: 7 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110411 Year of fee payment: 8 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120411 Year of fee payment: 9 |
|
| EXPY | Cancellation because of completion of term | ||
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120411 Year of fee payment: 9 |